Over 112,000 bottles of Amazon-branded extra-strength acetaminophen have been pulled from shelves after consumers discovered discolored pills inside, raising immediate safety concerns for families relying on this common pain reliever for their medicine cabinets.
Massive Recall Affects Three Bottle Sizes
Aurobindo Pharma USA, the New Jersey pharmaceutical company behind the product, launched the voluntary recall on September 18. The action impacts 14,640 bottles containing 200 caplets, 90,456 bottles with 500 caplets, and 7,836 bottles holding 1,000 caplets of Amazon Extra Strength Acetaminophen 500 mg. The company initiated the recall after receiving multiple consumer complaints about tablet discoloration, though the Food and Drug Administration has not identified what caused the pills to change color.
Amazon confirmed its cooperation with both the manufacturer and federal regulators. The company stated it voluntarily recalled specific lots of Amazon Basic Care Extra Strength Pain Relief acetaminophen 500mg caplets due to tablet discoloration reports in affected lots. The recall was coordinated with the manufacturer, Aurohealth, and the FDA.
Check Your Medicine Cabinet Now
Consumers should immediately inspect their acetaminophen bottles for specific lot numbers. For 200-count bottles, the affected lot is ACD125040A. The 500-count bottles carry lot numbers ACD124036A, ACD124030A, ACD124042A, ACD124048B, and ACD125010A. The 1,000-count bottles show lot number ACD124048A. All affected products were manufactured in India and distributed by Amazon.com Services LLC from Seattle, Washington.
The FDA has not disclosed any specific health risks associated with the discolored tablets, nor has the agency reported any injuries connected to the recall. This lack of transparency about potential dangers leaves families wondering whether the medication they gave their children or elderly parents posed hidden health threats.
Pattern of Foreign Manufacturing Concerns
This recall follows another voluntary action initiated September 3 by India-based Inventia Healthcare Ltd., which pulled 13,567 bottles of 25-milligram chlorthalidone tablets that failed dissolution specifications. The pattern of recalls from India-manufactured pharmaceuticals raises questions about quality control standards at overseas facilities supplying American consumers. Families deserve assurance that medications bearing trusted American brand names meet rigorous safety standards, regardless of where production occurs. The discoloration issue highlights the importance of inspecting medications before use and reporting any abnormalities to manufacturers and regulatory authorities immediately.